DAK urges authorities to make 'Tocilizumab' available for critical Covid19 patients

Doctors Association Kashmir (DAK) on Tuesday urged concerned authorities in Kashmir valley to make life-saving drug Tocilizumab available for critically-ill Covid-19 patients.

“The drug reduces the risk of death in seriously ill Covid-19 patients,” said DAK President and influenza expert Dr Nisar ul Hassan.

Quoting a study from the University of Michigan, Nisar said Covid-19 patients on ventilators who received a single dose of Tocilizumab injection were 45 percent less likely to die compared to those who did not receive the drug.

“Originally developed to treat rheumatoid arthritis, the drug combats the disease by quelling cytokine storm which is the hyper-immune response of the infected person to the virus,” Dr Nisar said.

“Mortality in Covid-19 patients has been linked to the presence of the cytokine storm induced by the virus,” he said adding that “excessive production of cytokines leads to respiratory failure and widespread tissue damage resulting in multi-organ failure and death.”

Dr Nisar said Tocilizumab suppresses the hyper-immune response by blocking receptor for a key cytokine known as interleukin-6 (IL-6) and improves survival rates and reduces mortality among Covid patients.

“Recently Indian Council of Medical Research (ICMR) in its revised protocol has allowed usage of the drug for patients with progressively increasing oxygen requirements and in mechanically ventilated patients not improving despite the use of steroids,” he said.

Dr Nisar said it is vitally important to know that there is no single magic bullet to treat the novel corona virus and several drugs in combination are needed to tackle the virus.

“With the approval of several therapies, combination of them given at the right time gives a good result,” he said.

“Apart from oxygen, moderate to severe patients are given steroids, remdesivir, convalescent plasma and Tocilizumab in various combinations,” he added.